Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$100.32 ▲ +0.22
(+0.22%)
MKT CAP: $6.55B • VOL: 771.7K
52W L $50 52W H $112
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$84
MEDIAN
$112
MEAN
$114
HIGH
$136
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE LNTH TAPE
LNTH // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $121.39 | $115.37 | 2025-02-14 | $91.29 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $126.40 | $118.38 | 2025-02-06 | $94.30 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $114.36 | $110.35 | 2025-01-29 | $96.31 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $102.33 | — | 2025-01-17 | $98.31 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $88.28 | $95.30 | 2025-01-09 | $89.28 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $119.38 | $104.33 | 2024-12-18 | $87.28 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $97.31 | $101.32 | 2024-12-04 | $93.30 | -4.3% | 48% | C |